ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1462	National Cancer Institute	Html	en	Gastrointestinal Carcinoid Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of gastrointestinal carcinoid tumors.	low-grade neuroendocrine tumors 0.396019 duodenal carcinoid tumor 0.397268 multifocal neuroendocrine tumors 0.421413 carcinoid patients 0.422833 relatively common carcinoids 0.388053 midgut neuroendocrine tumors 0.400819 midgut carcinoids 0.398106 carcinoid neuroendocrine tumors 0.530837 carcinoid heart failure. 0.412799 midgut carcinoid syndrome 0.494495 tract carcinoid tumors 0.466207 sporadic neuroendocrine tumors 0.41799 carcinoid heart disease 0.604399 multiple carcinoid tumors 0.498345 patients 0.441078 Pract Res Clin 0.384377 gastric carcinoids 0.406312 carcinoid symptoms 0.386144 Malignant carcinoid tumors 0.458841 ileal carcinoids 0.443228 carcinoid tumors 0.921678 Carcinoid Tumors section 0.552577 Gastrointestinal carcinoids 0.396139 term carcinoid 0.38666 gut neuroendocrine tumors 0.405828	gastric argyrophil carcinoid 0.39372 neuroendocrine tumors 0.772231 et al. 0.477186 carcinoid syndrome. 0.396106 renal carcinoid tumor 0.400621 rectal carcinoids 0.465534 Gastrointestinal Carcinoid Tumors 0.556816 rectal carcinoid patients 0.421651 carcinoids 0.607075 PUBMED Abstract 0.470567 multiple endocrine neoplasia 0.391617 frequent carcinoid tumor 0.405695 5-year survival 0.39049 neuroendocrine tumours 0.472335 neuroendocrine gastrointestinal tumors 0.422781 Pancreatic Neuroendocrine Tumors 0.446589 well-differentiated neuroendocrine tumors 0.443559 Abstract 0.585558 gastrointestinal carcinoid tumor 0.427766 carcinoid syndrome 0.595242 severe carcinoid heart 0.411522 gastroenteropancreatic neuroendocrine tumors 0.419971 metastatic carcinoid tumors 0.588139 duodenal carcinoids 0.494906	CLICK HERE
1540	National Cancer Institute	Html	en	Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies (PDQ®)–Health Professional Version	Information about how to weigh the strength of the evidence obtained in human studies of integrative, alternative, and complementary therapies for cancer.	strength 0.674769 evidence score 0.330764 clinical details 0.253336 strongest endpoint 0.346454 weak study design 0.389561 PDQ cancer information 0.609434 PDQ information 0.33766 Best Case Series 0.34796 clinical trials 0.245761 cancer information summary 0.520348 human studies 0.415104 breast cancer prevention 0.370124 numeric scale 0.249195 randomized trial 0.254175 study types 0.251887 study design 0.95862 design categories yields 0.398085 NCI’s PDQ 0.357199 cancer treatment studies 0.394746 PDQ Adult Treatment 0.532483 NCI PDQ cancer 0.476778 weakest design 0.286828 statistical strength 0.648901 complementary therapies 0.394252 human cancer 0.391957	proper assessment 0.249946 Therapies Editorial Board 0.336527 PDQ Integrative 0.333821 strongest design 0.2759 different treatments 0.250238 clinical findings 0.245005 case series 0.380662 progressive alphabetic scale 0.362349 similar results 0.25211 therapeutic endpoint 0.358766 Cause-specific mortality 0.243515 endpoint 0.41291 individual case reports 0.382311 particular treatments 0.266483 total mortality 0.246905 scientific strength 0.586275 National Cancer Institute 0.778424 Editorial Board 0.404104 PDQ documents 0.331784 various types 0.248384 anecdotal reports 0.254781 cancer-related images 0.244704 tumor response 0.253792 stronger study design 0.404144	CLICK HERE
1619	National Cancer Institute	Html	en	Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of myelodysplastic syndromes.	red blood cells 0.802655 Refractory anemia 0.210859 blast cells 0.213085 Myelodysplastic Syndromes Treatment 0.239976 blood cell transfusions 0.307965 PDQ cancer information 0.304981 Unclassifiable myelodysplastic syndrome 0.209687 white blood cells 0.599485 clinical trials 0.691716 mature blood cells 0.325517 cancer information summary 0.254688 clinical trial 0.37019 stem cell transplant 0.265266 Myeloid Leukemia Treatment 0.221437 patients 0.297669 blood cells 0.986637 standard treatment options 0.223147 immature cells 0.246396 treatment clinical trial 0.20763 NCI PDQ cancer 0.209619 myeloid stem cell 0.236773 myelodysplastic syndromes 0.714537 Treatment Editorial Board 0.221924 myeloid leukemia 0.323359 treatment 0.452708	stored stem cells 0.24091 abnormal cells 0.215174 immature blood cells 0.334065 blood stem cell 0.228491 cancer cells 0.239385 red blood cell 0.3261 acute myeloid leukemia 0.321377 patient 0.220132 treatment clinical trials 0.243695 blood stem cells 0.332989 National Cancer Institute 0.321589 blood-forming cells 0.209811 normal cells 0.213656 new treatment 0.246717 white blood cell 0.22258 bone marrow 0.630405 PDQ summary 0.205839 healthy blood cells 0.295483 cancer clinical trials 0.225848 live cells 0.215292 treatment options 0.241153 cancer 0.381961 standard treatment 0.271336 myelodysplastic syndrome 0.394764	CLICK HERE
1743	National Cancer Institute	Html	en	Photodynamic Therapy for Cancer	A fact sheet that explains photodynamic therapy, how it is administered, and indications and side effects of treatment.	cancer treatment 0.467161 skin cancer 0.463524 agent 0.509208 necessary nutrients 0.453814 blood cancers 0.455343 activating light 0.500969 cutaneous T-cell lymphoma 0.497644 surface tumors 0.462582 body 0.47526 different areas 0.455534 light sources 0.464075 healthy tissue 0.483908 bright indoor light 0.598285 U.S. Food 0.516598 specific wavelength 0.502289 certain cancers 0.465708 patients 0.455008 blood cells 0.468142 photosensitizing agent 0.45652 non-small cell lung 0.667463 photosensitizer 0.466135 symptoms 0.456503 particular type 0.455996 direct sunlight 0.514024 specific type 0.457687	treatment 0.479989 esophageal cancer 0.492936 photodynamic therapy 0.576544 nearby healthy tissue 0.481898 skin 0.463697 Drug Administration 0.510947 active form 0.454418 cancer cells 0.690083 fiber optic cable 0.49481 Barrett esophagus 0.454031 photosensitizers 0.460437 tumor cells 0.475849 normal cells 0.508255 PDT 0.970829 Extracorporeal photopheresis 0.455159 large tumors 0.503661 porfimer sodium 0.78695 fiber optic cables 0.493403 light-emitting diodes 0.456906 nearby cells 0.473123 tumors 0.505296 Laser light 0.464403 cell lung cancer 0.646935 nearby cancer cells 0.527607	CLICK HERE
1780	National Cancer Institute	Html	es	Tensión postraumática relacionada con el cáncer (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de la tensión postraumática y síntomas relacionados en los pacientes con cáncer, sobrevivientes del cáncer y miembros de la familia. Se discuten la evaluación y tratamiento de estos síntomas.	Coping with 0.312113 symptoms after 0.319304 Traumatic Stress Studies 0.314051 MOPP alternating with 0.310501 Trauma Stress 0.351142 Nerv Ment Dis 0.328654 Cella DF 0.451191 Arch Gen Psychiatry 0.346852 Leukemia Group B 0.316545 Post-traumatic stress after 0.328039 stress after childhood 0.327952 alternating with abvd 0.310501 Jacobsen PB 0.352264 Acute stress 0.312113 patients following autologous 0.318583 among holocaust survivors 0.314603 combat-related posttraumatic stress 0.348262 mental disorders 0.366349 criterio diagnóstico 0.338544 Green BL 0.343463 Human Stress 0.337499 traumatic stress symptoms 0.314194 cooperative clinical trials 0.320094 Hosp Community Psychiatry 0.312333 childhood cancer 0.324585	síntomas específicos tpt 0.311452 Widows MR 0.315755 tensión postraumática ttpt 0.310392 Grace MC 0.31562 Structured Clinical Interview 0.330114 postdisaster psychiatric disorders 0.311579 American Psychiatric Association 0.427992 bone marrow transplantation 0.440615 Cordova MJ 0.331735 posttraumatic stress 0.9934 Consult Clin Psychol 0.37836 life assessment 0.310879 Lindy JD 0.315479 marrow transplant recipients 0.310103 Event Scale 0.315869 Abnorm Psychol 0.310829 Kornblith AB 0.369198 Statistical Manual 0.340058 symptoms after treatment 0.312687 Anderson J 0.350583 stress symptoms 0.322303 Andrykowski MA 0.321927 post-traumatic stress 0.369384 after burn 0.311819	CLICK HERE
1811	National Cancer Institute	Html	es	Descripción del tratamiento de tumores de encéfalo y de médula espinal infantiles (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de varios tumores de encéfalo infantiles.	Altekruse SF 0.447856 American Academy 0.440446 Brain Tumor Registry 0.477956 pediatric cancer 0.464838 plexo coroideo 0.50432 largo plazo 0.465315 cancer center 0.498759 Children's National Health 0.432864 Declining childhood 0.43143 astrocitomas pilocíticos 0.47055 Instituto Nacional 0.460068 Reifenberger G 0.447846 World Health Organization 0.488687 Health Organization Classification 0.496391 Pediatric Brain Tumor 0.46738 tumor embrionario 0.530794 SAI Tratamiento 0.438882 tumores glioneuronales papilares 0.533183 Children's Oncology Group 0.486579 Childhood Cancer Survivor 0.446412 SNC primarios 0.433523 central nervous system 0.795553 pdq correspondiente tipo 0.466293 Smith MA 0.441598 Acta Neuropathol 0.450438	long-term survivors 0.443577 tumores papilares 0.526133 Organización Mundial 0.435085 United States 0.447735 subtipo patológico sumario 0.46642 Neuro Oncol 0.509938 PDQ Descripción 0.456005 Pediatr Blood Cancer 0.436965 PDQ Efectos tardíos 0.580122 National Cancer Institute 0.479004 Pollack IF 0.449126 tumor atípico 0.44433 Clin Oncol 0.579132 nervous system tumors 0.447762 sistema nervioso central 0.82435 childhood brain tumors 0.461864 brain tumor 0.932348 Kimmel Comprehensive Cancer 0.433441 Perry A 0.444221 tumores embrionarios 0.61933 newly diagnosed 0.441805 espinal infantiles recién 0.46155 childhood central nervous 0.442376 Wilmot Cancer Center 0.432289	CLICK HERE
1976	National Cancer Institute	Html	es	Tratamiento del cáncer de seno paranasal y de cavidad nasal (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno paranasal y de cavidad nasal.	glándula tiroides 0.30201 Neck Cancer 0.300319 siguientes procedimientos 0.303848 pequeño número 0.300609 siguientes aspectos 0.300986 estadio ii 0.30355 senos paranasales esfenoideos 0.304208 siguientes especialistas 0.300629 aire circula 0.300623 rayos x 0.300535 pequeñas marcas 0.300312 estadio ivc 0.301666 enlace drugs approved 0.300597 seno paranasal 0.995188 dientes flojos 0.300615 nasal envía señales 0.304954	dentaduras postizas 0.300692 National Cancer Institute 0.300148 tumores benignos 0.300663 siguientes riesgos 0.300156 fraccionamiento.ampliar radioterapia 0.301581 Instituto Nacional 0.300695 malla ayuda 0.300318 PDQ Tratamiento 0.300448 Physician Data Query 0.300682 siguientes sitios 0.301656 ganglio linfático mide 0.30303 aparato respiratorio ayuda 0.301084 siguientes enlaces 0.300254 senos paranasales etmoideos 0.307274 siguientes pruebas 0.30092	CLICK HERE
1982	National Cancer Institute	Html	es	Tratamiento del cáncer de tiroides (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de tiroides.	glándula tiroides 0.908295 estadios iva 0.233602 siguientes procedimientos 0.206098 ganglios linfáticos.ampliar cáncer 0.716308 hormona tiroidea 0.292738 radioterapia intraoperatoria 0.215525 siguientes aspectos 0.243621 menos.ampliar cáncer 0.315655 gen ret 0.208945 estadio ii 0.465746 enfermedad tiroidea 0.223963 ganglio linfático centinela 0.278708 vía oral 0.205075 rayos x 0.221349 estadio ivb 0.462997 estadio ivc 0.408027 enlace drugs approved 0.226007 ondas sonoras 0.222594 estadio iva 0.373015 órgano fonador 0.446375 National Cancer Institute 0.204974	tiroides causa efectos 0.252932 endocrina múltiple tipo 0.287058 hormonas tiroideas 0.209751 Instituto Nacional 0.209158 PDQ Tratamiento 0.229219 antecedentes familiares 0.2071 pacientes pastillas 0.209381 siguientes funciones 0.210244 Physician Data Query 0.218087 estadio iii 0.401226 centímetros.ampliar cáncer 0.275936 suficiente hormona tiroidea 0.209562 nódulo tiroideo 0.292185 Thyroid Cancer 0.21393 hormona calcitonina 0.209835 pequeña dosis 0.204395 pequeña parte 0.2042 células tiroideas 0.225287 cuerpo.ampliar cáncer 0.277585 nódulos tiroideos 0.301973 tiroides.ampliar cáncer 0.26979	CLICK HERE
3426	National Cancer Institute	Html	es	El uso de la hipertermia en el tratamiento del cáncer	Hoja informativa que explica en qué consiste la hipertermia (el tratamiento de los tumores con altas temperaturas) y sus efectos secundarios.	Lippincott Williams 0.53777 Lancet Oncology 0.561914 Gunderson LL 0.539005 Bast RC Jr 0.559948 Hildebrandt B 0.608355 Zee J 0.537016 undergoing surgical debulking 0.565384 causa efectos 0.537555 Gibbs FA Jr 0.56087 molecular basis 0.53797 intraperitoneal chemotherapy 0.537405 DeVita VT Jr 0.563586 termómetros minúsculos 0.539825 Kufe DW 0.535758 Kapp DS 0.536798 PubMed Abstract 0.959153 general medicamentos 0.53615 numerosos estudios 0.552283 Clinical Oncology 0.559745 Tepper JE 0.538345 International Journal 0.535346 Critical Reviews 0.540202 Isolation perfusion 0.539903 perfusión peritoneal hipertérmica 0.626548 hyperthermic peritoneal perfusion 0.599527	Pingpank JF 0.537893 numerosos obstáculos 0.535929 Libutti SK 0.60375 Carlson RW 0.535964 Wust P 0.612473 Decker Inc 0.534795 consecuencia quemaduras 0.537822 Issels RD 0.537803 combined treatment 0.542204 inserta pequeñas agujas 0.572325 también llamada terapia 0.570859 Churchill Livingstone 0.537458 Hellman S 0.534905 malignant peritoneal mesothelioma 0.597049 promising approach 0.54123 6th ed 0.538756 cuello uterino 0.631745 Alexander HR 0.602298 Clinical Radiation Oncology 0.587129 altas temperaturas 0.793884 Ahlers O 0.540177 Hahn GM 0.536167 Roemer RB 0.538179 Sreenivasa G 0.536365	CLICK HERE
3854	National Cancer Institute	Html	en	With Immunotherapy, Glimmers of Progress against Glioblastoma	Researchers who specialize in brain cancer are optimistic about immunotherapy’s prospects for improving outcomes in patients with this aggressive form of brain cancer.	small trial testing 0.468005 Dr. Gilbert 0.515178 tumor-specific immune response 0.48073 malignant brain tumor 0.510587 early-phase trial testing 0.467191 dendritic cells 0.61475 operable glioblastoma 0.578819 specialized endothelial cells 0.558383 dendritic cell vaccines 0.48246 clinical trials 0.590613 glioblastoma cells 0.815515 12-patient clinical trial 0.463613 so-called peptide vaccine 0.471528 immature immune cells 0.5807 patients 0.746073 brain cancer 0.489359 healthy brain cells 0.678016 immune-based treatments 0.561628 CAR T-cell therapy 0.537367 glioblastoma 0.965748 brain tumor immunotherapy 0.646246 contractile cells 0.490726 EGFRvIII-positive glioblastoma 0.583166 checkpoint inhibitors 0.623905 glioblastoma patients 0.63769	CAR T cells 0.567214 Dr. Sampson 0.590733 advanced glioblastoma 0.567342 delivery cancer treatments 0.470619 trial testing 0.590548 immune response 0.549878 Dr. Lim 0.552388 tumor cells 0.483775 small randomized trial 0.471443 advanced melanoma 0.473209 immune cells 0.646076 trial testing rindopepimut 0.489783 Comprehensive Cancer Center 0.46874 CMV-infected cells 0.470459 newly diagnosed glioblastoma 0.754821 early-stage clinical trials 0.589931 engineering cells 0.471397 tumor immunotherapy program 0.633115 cells 0.839043 dendritic cell vaccine 0.705918 phase I/II trial 0.478298 larger randomized trials 0.595338 cancer 0.501031 glioblastoma tumors 0.562465	CLICK HERE